Literature DB >> 27748738

Risk factors of clinically refractory CMV reactivation following allogeneic HSCT: a single-center study in China.

X Bao1,2,3, Q Zhu4, S Xue1,2,3, Y Xu1,2,3, X Ma1,2,3, F Chen1,2,3, X Hu1,2,3, Z Zhu1,2,3, S Chen1,2,3, A Sun1,2,3, D Wu1,2,3, Y Song5, H Qiu1,2,3.   

Abstract

Mesh：

Year:  2016        PMID： 27748738     DOI： 10.1038/bmt.2016.231

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

Review 1.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

2.  Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow.

Authors:  H D Ottinger; D W Beelen; B Scheulen; U W Schaefer; H Grosse-Wilde
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

3.  Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.

Authors:  W G Nichols; L Corey; T Gooley; W L Drew; R Miner; M Huang; C Davis; M Boeckh
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

4.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

Authors:  Tobias Feuchtinger; Kathrin Opherk; Wolfgang A Bethge; Max S Topp; Friedhelm R Schuster; Eva M Weissinger; Mohamad Mohty; Reuven Or; Michael Maschan; Michael Schumm; Klaus Hamprecht; Rupert Handgretinger; Peter Lang; Hermann Einsele
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

5.  Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.

Authors:  R Trenschel; S Ross; J Hüsing; H Ottinger; A Elmaagacli; M Roggendorf; U W Schaefer; V Runde
Journal:  Bone Marrow Transplant       Date:  2000-03       Impact factor: 5.483

6.  Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.

Authors:  H J Deeg; D Lin; W Leisenring; M Boeckh; C Anasetti; F R Appelbaum; T R Chauncey; K Doney; M Flowers; P Martin; R Nash; G Schoch; K M Sullivan; R P Witherspoon; R Storb
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

7.  Risk factors for cytomegalovirus infection after human marrow transplantation.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

8.  Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.

Authors:  Sébastien Hantz; Françoise Garnier-Geoffroy; Marie-Christine Mazeron; Isabelle Garrigue; Pierre Merville; Catherine Mengelle; Lionel Rostaing; Franck Saint Marcoux; Marie Essig; Jean-Philippe Rerolle; Sébastien Cotin; Raphaëlle Germi; Sylvie Pillet; Yvon Lebranchu; Pascal Turlure; Sophie Alain
Journal:  J Antimicrob Chemother       Date:  2010-10-20       Impact factor: 5.790

9.  Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source.

Authors:  P Chevallier; I Hebia-Fellah; L Planche; T Guillaume; C Bressolette-Bodin; M Coste-Burel; F Rialland; M Mohty; B-M Imbert-Marcille
Journal:  Bone Marrow Transplant       Date:  2009-11-23       Impact factor: 5.483

Review 10.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.